Annual Drug Patent Expirations for YUPELRI
Yupelri is a drug marketed by Mylan Ireland Ltd and is included in one NDA. It is available from one supplier. There are nineteen patents protecting this drug.
Drug patent litigation for YUPELRI.
This drug has sixty-four patent family members in thirty-one countries.
The generic ingredient in YUPELRI is revefenacin. One supplier is listed for this compound. Additional details are available on the revefenacin profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
